Even after soaring by more than 125% over the past week, shares of Aurora Cannabis (NYSE: ACB) still have plenty of upside.
So says investment bank Ladenburg Thalmann, which reiterated its buy rating on Aurora's stock on Monday. Even after cutting his price target in half, analyst Glenn Mattson says Aurora's shares are still worth significantly more than the price at which they're currently trading. Mattson thinks the marijuana industry leader's stock is worth at least $18, which is about 24% more than shares were fetching at 1:15 p.m. EDT Tuesday.
Mattson commended Aurora for its better-than-expected sales growth in its fiscal third quarter, which ended March 31. The cannabis producer's total net revenue surged 35% sequentially to $75.5 million, driven in part by a 24% jump in recreational consumer cannabis sales to $41.5 million. Those figures were well above Mattson's projections for total net revenue and consumer cannabis sales of $67.6 million and $36.6 million, respectively.
Mattson also applauded Aurora's newfound financial discipline. The previously free-spending company has instituted a series of cost-reduction initiatives to slow its cash burn and shore up its balance sheet. In light of these efforts, he believes Aurora will soon begin to generate positive cash flow from its home market of Canada.
"We think ACB can become a solid cash flow generator simply from the Canadian operations and, with a strong market position in Canada, the company can create significant value from here based on this one market," Mattson said.
Looking ahead, he expects Aurora to eventually build a significant presence in the U.S., where marijuana sales are forecast to be as much as 12 times higher than the Canadian cannabis market by 2024.
"We do think that it will look to expand into the U.S. but not until federal legality is more clear," Mattson said.